We are pleased to announce that Boston Healthcare Associates will now be part of a new company called Veranex.

This article generalizes the process to provide a hyper-simplified answer for investors and CEOs, and sales & marketing executives of MedTech companies, needing this crucial piece of information to make sound investment decisions or plan and allocate organizational resources.

Several recent national-level policy changes highlight an accelerating digital transformation of healthcare in Germany, building on the Digital Healthcare Act (DVG) of 2020. In January 2021, the German Federal Government passed the draft of a law that aims to now include digital nursing and elderly care applications (DiPAs) into statutory health insurance coverage complementing coverage for digital health apps (DiGAs).

The NCCN 2021 Annual Conference convened virtually March 18-20, drawing attendees from more than 40 countries to discuss updates to NCCN's Oncology Clinical Practice Guidelines, new and emerging therapies, best practices in oncology care, as well as keynote sessions on HPV vaccinations, racial disparities in guideline-adherent cancer care, and effects of the pandemic on cancer care.

A leading global device manufacturer faced a pricing strategy challenge and partnered with BHA to identify appropriate prices for a suite of three products aimed at the low-end, mid-range, and high-end of the urology market.

Currently, there are approximately 2800+ county-level administrative regions in China, and over 70% of the total Chinese population resides in these counties, more commonly referred to as “the rural areas of China”.

As the new year begins, we are looking ahead to four key megatrends that we expect to shape the landscape in the year to come.

As a result of Brexit, the In Vitro Diagnostic Medical Device Regulations (IVDR) will not apply to Great Britain. Unlike Great Britain, the IVDR will apply in Northern Ireland from 26 May 2022.

Alcon, a global leader in eye care, collaborated with Boston Healthcare to conduct a Time-and-Motion Study to support the value communication of its novel swept-source optical coherence tomography biometer, ARGOS®.

In November 2020, two years following the implementation of the national centralized tender program that started with biopharmaceuticals, the first medical device was targeted - drug-eluting coronary stents.